FDA granted accelerated approval for vinCRIStine sulfate LIPOSOME injection (Marqibo, Talon Therapeutics, Inc.) for the treatment of adult patients with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies. August 9, 2012. More Information: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm315111.htm
| This email was sent to kostikblog@ukr.net using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420 |  |
